Company Profile

Ipsen S.A. (OTC: IPSEY)
1:59 PM UTC, 07/03/24
Last: $30.81 Change: +0.53 %Change: +1.75% Volume: 277
Detailed Quote
Open: $ 30.81   Volume: 277
High: $ 30.81   Yield(%) 0.77
Low: $ 30.81   P/E Ratio (ttm): 14.52
Dividend ($): 0.24   Market Cap ($): 10.10B
EPS ($) n/a   Shares Out: 330.56M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): -7.36
% Price Change (last 13 weeks): 7.03
% Price Change (last 26 weeks): 2.58
% Price Change (last 52 weeks): 2.18
% Price Change (year to date): 2.56
Management Effectiveness
Return on Equity (%): 17.13
Return on Assets (%): 10.29
Return on Invested Capital (%): 13.48
Profitability
Gross Profit Margin (%): 75.10
Net Profit Margin (%): 19.73
Operating Profit Margin (%): 20.75
Price & Volume
50-day Moving Average: $22.29
200-day Moving Average: $23.06
Avg. Daily Vol. (last 50 days): 712
Avg. Daily Vol. (last 200 days): 1,094
52-wk high: $34.34
52-wk low: $26.97
Bid: $n/a
Ask: $n/a
Company Information
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.
Ipsen S.A.
65, quai Georges Gorse
Boulogne-Billancourt IF 92650

Phone: 33.1.58.33.50.00
Fax: 33.1.58.33.50.01
http://www.ipsen.com
Per Share Data
Earnings (1year) ($): 2.11
Annual Dividend ($): 0.24
Current P/E Ratio (ttm): 14.52
Book Value ($): 12.78
Cash Flow ($): 3.08
Valuation Ratios
Price/Earnings (x): 14.52
Price/Sales (x): 2.94
Price/Book (x): 2.33
Price/Cash Flow (x): 10.90
Financial Strength
Quick Ratio (x): 0.99
Current Ratio (x): 1.17
LT Debt/Equity (x): 8.93
Total Debt/Equity (x): 12.10



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2020 Wall Street Horizon, Inc.